Entropy Neurodynamics announced topline Cohort 1 results from its Phase 2 trial of TRP-8803 (IV-infused psilocin) in treatment-resistant binge eating disorder. The results — which the company believes represent the world's first reported clinical efficacy data for precision-controlled IV-infused psilocin — significantly exceeded management expectations. Cohort 1 results showed 50% of patients achieving complete clinical remission (zero binge-eating episodes in four weeks post-treatment) and 100% of patients achieving clinically meaningful improvement (30% or greater improvement from baseline). Additional findings included a 74% reduction in weekly binge-eating episodes, 58-60% reductions in anxiety and depression scores, and a 63% improvement in life satisfaction across all Cohort 1 patients. The Independent Data Safety Monitoring Board has endorsed progression to Cohort 2 without protocol modification, confirming TRP-8803's favourable safety profile. Cohort 2 is fully enrolled, with dosing expected in August 2026 and final Phase 2 results expected in Q4 CY2026.

Entropy Neurodynamics Ltd (ASX:ENP) rose 6.25% in the latest session, with shares trading at $0.034 on 7 Jul 2026. The move draws investor attention to the latest developments at the company and what they may mean for the near and longer-term investment case. For investors evaluating Entropy Neurodynamics Ltd, understanding the company's business, the significance of recent announcements and the key risks and opportunities provides an essential foundation for informed decision-making.

Company Overview

Entropy Neurodynamics Limited is a clinical-stage biotechnology company developing precision-controlled intravenous psilocin therapies for treatment-resistant neuropsychiatric conditions. The company's lead compound, TRP-8803, delivers psilocin (the active metabolite of psilocybin) via intravenous infusion, enabling precise dose control and predictable pharmacokinetics that are not achievable with oral psilocybin formulations. The company's differentiated approach — IV delivery enabling controlled onset, peak intensity and offset — addresses key limitations of conventional oral psilocybin therapy including variable onset times, prolonged session duration and limited dose adjustment capability once administered.

Business at a Glance

Entropy Neurodynamics trades on the Australian Securities Exchange under the ticker ASX:ENP. The company is conducting Phase 2 clinical trials of TRP-8803 in treatment-resistant binge eating disorder.

• TRP-8803 — IV-infused psilocin for treatment-resistant neuropsychiatric conditions

• Precision-controlled delivery — predictable onset, peak and offset vs oral psilocybin

• Phase 2 BED trial — binge eating disorder in treatment-resistant patients

• Cohort 1 results — 50% remission, 100% clinically meaningful improvement

• Cohort 2 — fully enrolled, dosing expected August 2026

Strategic Positioning

Entropy's strategic differentiation is based on its precision-controlled IV psilocin delivery platform, which the company believes addresses fundamental limitations of oral psilocybin as a clinical tool. The shorter, more controllable session enabled by IV delivery has potential advantages for clinical scalability. The strong Cohort 1 results in BED provide a foundation for potential expansion into additional neuropsychiatric indications, regulatory engagement and partnership discussions.

Recent Market Context

The psychedelic therapeutics sector has attracted significant scientific and commercial attention, with psilocybin and other compounds demonstrating clinical activity in depression, addiction and other treatment-resistant conditions. Entropy's IV psilocin approach is differentiated from the broader oral psilocybin field. Treatment-resistant binge eating disorder represents a condition with significant unmet medical need — approximately one-third of epilepsy patients are treatment-resistant, and BED has limited effective treatment options in the existing therapeutic toolkit.

Why Investors May Be Watching Entropy Neurodynamics Ltd

The Cohort 1 results are the primary catalyst that has driven investor attention to ENP. The combination of 50% remission rates and 100% clinically meaningful improvement across all measured domains in a treatment-resistant BED population represents a very strong early-phase clinical signal. Cohort 2 results, expected in Q4 CY2026, represent the next major value-defining event for the company.

The Psychedelic Therapeutics & Neuropsychiatry Industry

The psychedelic therapeutics industry is at an early but rapidly evolving stage, with regulatory frameworks for psilocybin and related compounds developing in multiple jurisdictions. MDMA-assisted therapy has received regulatory setbacks in the US, making the development path for psilocybin-based therapies important to monitor. IV-delivered psychedelics represent a more controlled and clinically manageable format than oral approaches, which could potentially offer advantages in regulatory engagement and clinical adoption if efficacy is demonstrated.

Where Entropy Neurodynamics Ltd Fits Within the Sector

Entropy Neurodynamics occupies a specific and differentiated position within the ASX-listed psychedelic therapeutics sector, with an IV delivery platform that is distinct from the broader oral psilocybin field. Its world-first clinical results position it as a pioneer in precision-controlled psychedelic therapy.

Key Catalysts Investors May Monitor

Investors following Entropy Neurodynamics Ltd may monitor several developments:

• Cohort 2 Phase 2 results — expected Q4 CY2026

• Cohort 2 dosing commencement — expected August 2026

• Durability data — longer-term follow-up from Cohort 1 patients

• Regulatory engagement — discussions with regulatory authorities on development pathway

• Partnership discussions — potential licensing or collaboration with larger pharmaceutical companies

• Multi-indication expansion planning — additional neuropsychiatric conditions

• Biomarker and EEG analysis results from Cohort 1

Key Risks and Uncertainties

Entropy is a clinical-stage company with binary risk from clinical trial outcomes. Phase 2 results in Cohort 2 may not replicate the Cohort 1 results, and the small sample size in Cohort 1 (6 patients) means results should be interpreted cautiously. Regulatory pathways for psychedelic-assisted therapies remain evolving and uncertain. The company requires ongoing capital to fund its clinical programme. The MDMA regulatory setback in the US creates uncertainty for the broader psychedelic therapeutics category.

Balanced Outlook

ENP's near-term trajectory is dominated by Cohort 2 — dosing in August 2026 and results by end of 2026. Positive Cohort 2 results replicating Cohort 1 would be a major clinical milestone supporting regulatory engagement and partnership discussions. The Cohort 1 results also open the door to multi-indication expansion planning, which represents longer-term optionality for the TRP-8803 platform if further clinical validation is achieved.

Considerations That May Support Interest

• World-first IV psilocin clinical efficacy results in treatment-resistant BED

• 50% complete remission and 100% clinically meaningful improvement — exceptional signals

• Multi-domain improvement across behaviour, mood, anxiety and quality of life

• Precision-controlled delivery differentiating from conventional oral psilocybin

• DSMB endorsement of protocol for Cohort 2 without modification

Considerations That Warrant Caution

• Cohort 1 sample size of 6 patients — results should be interpreted with appropriate caution

• Clinical-stage company with binary risk from Cohort 2 trial results

• Regulatory pathway for psychedelic therapeutics remains evolving and uncertain

• MDMA regulatory setbacks create uncertainty for the broader category

• Ongoing capital requirements before commercial stage

Conclusion

Entropy Neurodynamics has delivered what it describes as world-first clinical efficacy data for precision-controlled IV-infused psilocin, with Cohort 1 results that — while from a small patient group — show very strong signals across remission rates, symptom improvement and multi-domain quality-of-life outcomes in a challenging treatment-resistant population. For investors asking whether ENP deserves attention, the Cohort 1 results provide genuine early-stage clinical validation of an innovative platform in a field attracting significant scientific and commercial interest. The key near-term question is whether Cohort 2 — expected to report by end of 2026 — replicates these findings. A positive Cohort 2 result would represent a transformative milestone for the company.